The phase I,II clinical study of cancer vaccine for intractable malignant tumor expressing MAGE-A4-antigen

The phase I,II clinical study of cancer vaccine for intractable malignant tumor expressing MAGE-A4-antigen - The clinical study of cancer vaccine for intractable malignant tumor

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001999

Enrollment

Registered

2009-05-22

Start date

2009-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intractable malignant tumors expressing MAGE-A4 antigen

Interventions

CHP-MAGE-A4 injection of 100 &amp

micro

g CHP-MAGE-A4 injection of 300 &amp

g and concomittant injection of OK-432 as an adjuvant

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cancer patients expressing MAGE-A4 antigen

Exclusion criteria

Exclusion criteria: HIV positive, autoimmune diseases,pregnancy,breast feeding

Design outcomes

Primary

Measure	Time frame
the adverse events and the ability to induce antigen specific immune responses	—

Countries

Japan

Contacts

Public ContactTakahiro Tsuchikawa

Hokkaido University Graduate School of Medicine Department of Surgical Oncology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026